Cite

HARVARD Citation

    Armuzzi, A. et al. (2019). The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory bowel diseases. 25 (3), pp. 568-579. [Online]. 
  
Back to record